Skip to main content
Home

Parliamentary Questions


Question Without Notice No. 870 asked in the Legislative Council on 20 August 2019 by Hon Aaron Stonehouse

Parliament: 40 Session: 1

MEDICAL CANNABIS — PRESCRIPTIONS

870. Hon AARON STONEHOUSE to the parliamentary secretary representing the Minister for Health:

I refer the minister to my question without notice 34 of 14 March 2018, regarding the need to dramatically reduce the red tape involved in the prescription of medicinal cannabis. Almost 18 months later, I ask the following.

(1) Is it true that a general practitioner in Western Australia wishing to prescribe medicinal cannabis must, as a requirement of the WA Department of Health, submit a supporting letter from a specialist prior to an application being approved by the department, despite the Therapeutic Goods Administration itself having no such requirement?

(2) Is it true that, by comparison, the clinical justification, treatment and monitoring plans provided by GPs in New South Wales, Victoria and Queensland are accepted in each of those states without the need for specialist sign-off?

(3) What is the average wait time for, and cost of, a specialist appointment in WA?

(4) If disparities exist, what is the McGowan government doing to ensure that eligible patients in WA have the same ease of access to medicinal cannabis and are not unduly disadvantaged when compared with their peers in other parts of Australia?

Hon ALANNA CLOHESY replied:

I thank the honourable member for some notice of the question. I am advised of the following.

(1) Yes.

(2) Different requirements apply in each jurisdiction.

(3) The Department of Health does not collect this information.

(4) Efforts to improve access to medicinal cannabis are continuing. The Department of Health is progressively reducing regulatory restrictions, including providing prescribing approval decisions, when required, electronically in two days, and a recent extension to the duration of approvals issued. The Department of Health is also reviewing approval requirements, including the need for specialist support, in line with accumulating evidence surrounding medicinal cannabis and to maintain consistency with other jurisdictions.